Publikationen

Hier finden Sie einen Überblick über die Autoren, sowie die Titel mit Quellenangaben seit 1983 bis 2018. Einige der Dissertationen sind noch in Arbeit.

Autoren arap Quelle
(Buch, Zeitschriten, Seiten)
Jahr Impact-Factor
1 Lang W., Lang M., Kornhuber A., Deecke L., Kornhuber HH. Human cerebral potentials and visuomotor learning. Pflugers Arch. 1983 Dec; 399(4): 342-4. 1983
2 Schreiber H., Lang M., Lang W., Kornhuber A., Heise B., Keidel M., Deecke L., Kornhuber HH. Frontal hemispheric differences in the Bereitschaftspotential associated with writing and drawing. Hum Neurobiol. 1983; 2(3):197-202. 1983
3 Schreiber H., Lang M., Lang W., Kornhuber A., Heise B., Keidel M., Deecke L. Frontal hemispheric differences in the Bereitschaftspotential associated with writing and drawing. Human Neurobiol 2: 197 - 202. 1983 1.61
4 Lang W., Lang M., Heise B., Deecke L., Kornhuber HH. Brain potentials related to voluntary hand tracking, motivation and attention. Hum Neurobiol. 1984; 3(4): 235-40. 1984
5 Deecke L., Heise B., Kornhuber HH., Lang M., Lang W. Brain potentials associated with voluntary manual tracking: bereitschaftspotential, conditioned premotion positivity, directed attention potential, and relaxation potential. Anticipatory activity of the limbic and frontal cortex. Ann NY Acad Sci. 1984; 425:450-64. 1984
6 Lang W., Lang M., Kornhuber A., Gallwitz A., Kriebel J. Neuropsychological and neuroendocrinological disturbances associated with extracerebral cysts of the anterior and middle cranial fossa. Eur Arch Psychiatry Neurol Sci. 1985; 235(1): 38-41. 1985
7 Deecke L., Kornhuber HH., Lang W., Lang M., Schreiber H. Timing function of the frontal cortex in sequential motor and learning tasks. Hum Neurobiol. 1985; 4(3): 143-54. 1985
8 Deecke L., Kornhuber HH., Lang W., Lang M., Schreiber H. Timing function of the frontal cortex in sequential motor and learning tasks. Human Neurobiology 4: 143-154. 1985 1.61
9 Frank P., Maunz M., Rösch R., Schreiber H. Mediscript. Kommentierte Staatsexamsfragen zum 2. Abschnitt der ärztlichen Prüfung. Mediscript-Verlag. 1985
10 Lang W., Lang M., Kornhuber A., Kornhuber HH. Electrophysiological evidence for right frontal lobe dominance in spatial visuomotor learning Arch Ital Biol. 1986 Feb; 124(1): 1-13. 1986
11 Decke L., Kornhuber HH., Schreiber H., Lang M., Lang W., Kornhuber A., Heise B., Keidel M. Bereitschaftspotential associated with writing and drawing. In: McCallum WV, Zappoli R, Denoth F (eds). Cerebral psychophysiology: Studies in eventrelated potentials. EEG Suppl 38: 245-247. Elsevier, Amsterdam. 1986
12 Lang M., Lang W., Diekmann V., Kornhuber HH. The frontal theta rhythm indicating motor and cognitive learning. Electroencephalogr Clin Neurophysiol. Suppl. 1987; 40: 322-7. 1987
13 Lang M., Lang W., Uhl F., Kornhuber A., Deecke L., Kornhuber HH. Slow negative potential shifts indicating verbal cognitive learning in a concept formation task. Hum Neurobiol. 1987; 6(3): 183-90. 1987
14 Deecke L., Uhl F., Spieth F., Lang W., Lang M. Cerebral potentials preceding and accompanying verbal and spatial tasks. Electroencephalogr Clin Neurophysiol Suppl. 1987. 40: 17-23. 1987
15 Lang M., Lang W., Diekmann V., Kornhuber HH. The frontal theta rhythm indicating motor and cognitive learning. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40: 322-7. 1987
16 Lang M., Lang W., Uhl F., Kornhuber A. Slow negative potential shifts in a verbal concept formation task. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40: 335-40. 1987
17 Lang W., Lang M., Kornhuber A., Deecke L., Kornhuber HH. Slow negative potential shifts in conflicting response paradigms. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40: 53-8. 1987
18 Lang W., Lang M., Goldenberg G., Podreka I., Deecke L. EEG and rCBF evidence for left frontocortical activation when memorizing verbal material. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40: 328-34. 1987
19 Uhl F., Lang W., Lang M, Kornhuber A, Deecke L. Cortical slow potentials in verbal and spatial tasks--the effect of material, visual hemifield and performing hand. Neuropsychologia. 1988; 26(5): 769-75. 1988
20 Lang W., Lang M., Kornhuber A., Diekmann V., Kornhuber HH. Event-related EEG-spectra in a concept formation task. Hum Neurobiol. 1988;6(4): 295-301. 1988
21 Lang W., Lang M., Uhl F., Kornhuber A., Deecke L., Kornhuber HH. Left frontal lobe in verbal associative learning: a slow potential study. Exp Brain Res. 1988;70(1): 99-108. 1988
22 Lang W., Lang M., Uhl F., Koska C., Kornhuber A., Deecke L. Negative cortical DC shifts preceding and accompanying simultaneous and sequential finger movements. Exp Brain Res. 1988;71(3): 579-87. 1988
23 Lang W., Lang M., Podreka I., Steiner M., Uhl F., Suess E., Müller C., Deecke L. DC-potential shifts and regional cerebral blood flow reveal frontal cortex involvement in human visuomotor learning. Exp Brain Res. 1988; 71(2): 353-64. 1988
24 Schreiber H., Stolz G., Rothenmeier J., Kornhuber HH., Born J. Prolonged latencies of the N2 and P3 of the auditory event-relatex potential in children at risk for schizophrenia. Eur Arch Psy Clin Neuro 238: 185-188. 1989 3.49
25 Schreiber H., Stolz-Born G., Rothmeier J., Kornhuber AW., Born J., Kornhuber HH. Evoked brain potentials and psychometric data in children at risk for schizophrenia. In: Deecke L. JC Eccles. VB mountcastle (eds.). From Neuron to Action. An Appraisal of fundamental and clinical Research. Berlin. Heidelberg. New.York: Springer. Pp: 489-494. 1990
26 Schreiber H., Stolz-Born G., Rothmeier J., Kornhuber AW., Born J., Kornhuber HH. Evoked brain potentials and psychometric data in children at risk for schizophrenia. In: Deecke L, JC Eccles, VB Mountcastle (eds.). From Neuron to Action. An Appraisal of fundamental and clinical Research. Berlin: Springer. Pp:489-494. 1990
27 Schreiber H., Stolz-Born G., Kornhuber HH., Born J. Delayed endogenous evoked brain potentials in two independent groups of children at risk for schizophrenia. In:  Brunia CHM, AWK Gailard, A Kok (eds.). Psychophysiological Brain Research. Tilburg University Pres. Pp: 227-231. 1990
28 Kornhuber ME., Kornhuber HH., Kornhuber J., Schreiber H.., Westphal KP. Schizophrenia - autoimmune asthenia of the glutamate receptor? In: Stefanis CN et al (eds). Psychiatry: A world perspective - Volume 2. Elsevier, Amsterdam. Pp: 215-219. 1990
29 Rothmeier J., Schreiber H., Fröscher W. Myositis ossificans circumscripta nach ungewöhnlichem "Hirtrauma". Fortschr. Med. 108 (21): 415-416. 1990
30 Schreiber H., Stolz-Born G., Rothmeier J., Kornhuber A., Kornhuber HH., Born J. Endogenous event-related brain potentials and psychometric performance in children at risk for schizophrenia. Biol Psychatry 30: 177-189. 1991 8.28
31 Bayer H., Frei-Kleiner S., Schreiber H. Schlafporbleme und nervöse Störungen. Da hilft die Passionsblume. Studie mit 1377 Patienten.  Ärztliche Praxis 43(21): 13-16. 1991
32 Schreiber H., Kornhuber HH. Das Parkinson-Syndrom. Aktuelle Entwicklungen zur Pathogenese, Diagnostik und Therapie. Münch Med Wochenschr 134: 302.305. 1992
33 Schreiber H., Stolz-Born G., Rothmeier J., Kornhuber HH., Rothenberger A., Born J. Kinder schizophrener Eltern - Neurophysiologische Hinweise auf die Hypofrontalität als Risikofaktor.  Baumann P (ed). Biologische Psychiatrie der Gegenwart. Wien. New-York: Springer. pp: 385-389. 1992
34 Schreiber H., Westarp MP., Hülser PJ., Westphal KP., Wollinsky KH., Westarp ME., Mauch E., Laufen H., Kornhuber HH. Dokumentation von Zeichen chronischer Entzündungen und multifokaler Demyelinisierung des ZNS Motoneuronerkrankungen. Verh Dt Ges Neurol 7: 701 - 704. 1992
35 Schreiber H., Stolz-Born G., Rothmeier J., Kornhuber HH., Rothenberger A., Born J. Kinder schizophrener Eltern - Neurophysiologische Hinweise auf die Hypofrontalität als Risikofaktor.  In: Baumann P (ed). Biologische Psychiatrie der Gegenwart. Wien, New-York: Springer. Pp: 385-389. 1992
36 Westphal KP., Bauer J., Laupheimer H., Schreiber H., Westarp ME., Hülser PJ., Baumgärtner K., Wollinsky KH., van Eick H., Kornhuber HH. Verlangsamte Progression der ALS während intrathekaler Therapie mit Interferon beta. Verh Dr Ges Neurol 7: 699-700. 1992
37 Schreiber H., Stolz-Born G., Kornhuber HH., Born J. Event-related potential correlates of impaired selective attention in children at high-risk for schizophrenia.  Biol Psychiatry 32:634-651. 1992 8.28
38 Schreiber H., Stolz-Born G., heinrich H., Kornhuber HH., Born J. Attention, cognition, and motor perseveration in adolescents at genetic risk for schizophrenia and control subjects. Psychiat Res 44: 125-140. 1992 2.52
39 Born J., Schwab B., Schwab R., Schreiber H. Acute and long-term effects of audrenocorticotropin and dexamethasone on the auditory brainstem response in multiple sclerosis patients. J Neurol 241: 75-80. 1993 3.47
40 Westarp ME., Barmann P., Rössler J., Geiger E., Westphal KP., Schreiber H., Fuchs D., Westarp MP., Kornhuber HH Antiretroviral therapy in sporadic adult amyothrophic lateral sclerosis. NeuroReport 4: 819-822. 1993 1.65
41 Schreiber H., Kornhuber HH. Heutiger Stand der medikamentösen Therapie des Parkinson-Syndroms. Jatros Neurologie 9: 28-40. 1993
42 Schreiber H., Born J., Stolz-Born G., Rothmeier J., Jürgens R., Rothenberger A., Kornhuber A., Becker W., Kornhuber HH Schizophrenie - Zentralnervöse Funktionsdefizite bei Risikokindern. TW Neurologie Psychiatri, 7: 728-737. 1993
43 Schreiber H., Stolz-Born G., Kornhuber HH., Born J. Event-related potential correlates of selective attention in children at genetic risk for schizophrenia. In. Heinze HJ & Münte TF (eds.). New developments in event-related potentials. Boston: Birkhäuser. 319-324. 1993
44 Schreiber H., Seack K., Born J., Wallner B., Friedrich JM., Kornhuber HH. Hirnmorphologische Befunde bei Jugendlichen mit und ohne genetische Schizophrenierisiko: Eine vergleichende NMR-Studie. In: Deecke L & Lang W (Hrsg.). Kongressband des Deutsch-Österreichischen Neurologenkongresses. 1993
45 Westarp ME., Hülser PJ., Schreiber H., Westphal KP., Kolde G., Horn-Jörgensen R., Clausen Föhring B., Westarp NP., Kornhuber HH. Human retrovirus involvement in amyotrophic lateral sclerosis: A rationale for antiretroviral therapy? In: Serratrice G, Pellissiert JF, Pouget J, Blin O, Branger D, Turc F, Azulay JP (eds.). Systeme nerveux, muscles et maladies systemiques - acquistions recentes. Expasion Scientifique Francaise, Paris. Pp:250-263. 1993
46 Marshall L., Mölle M., Schreiber H., Fehm HL., Born J. Scalp recorded direct current potential shifts associated with the transition to sleep in man. Electroencephalogr Clin Neurophysiol 91: 346-352. 1994 2.29
47 Kornhuber AW., Lang W., Becker M., Uhl F., Goldenberg G., Lang M. Unimanual motor learning impaired by frontomedial and insular lesions in man. J Neurol. 1995 Sep; 242(9): 568-78 1995
48 Westarp ME., Schreiber H., Westarp MP., Westphal KP., Mauch E., Kornhuber HH. Cerebral magnetic resonance imaging pathology and cerebrospinal fluid proteins in sporadic amyotrophic lateral sclerosis. Clin Neuropathol 4: 228-232. 1995 1.04
49 Wollinsky KH., Minde A., Schreiber H., Kluger P., Mehrkens HH  Effektivität der Heimbeatmung bei Kleinkindern und Säuglingen. Med Klein 90: 57-59. 1995 0.47
50 Schreiber H., Kornhuber HH. Biologische Marker in der Psychiatrie: Forschungskonzept und bisherige Ergebnisse am Beispiel der Schizophrenie.  In: Lieb, K; Riemann, D; Berger, M (Hrsg.). Biologisch-psychiatrische Forschung. Stuttgart: Gustav Fischer Verlag. 196-218. 1995
51 Schreiber H., Rothmeier J., Becker W., Jürgens R., Born J., Stolz-Born G., Westphal KP., Kornhuber HH Comparative assessment of saccadic eye movements. Psychomotor and cognitive performance in schizophrenics, their first-degree relatives and control subjects. Acta Psychiat Scand 91: 195-201. 1995 4.22
52 Schreiber H., Stolz-Born G., Pietroqsky R., Kornhuber HH., Fehm HL., Born J. Improved event-related poential signs of selective attention after the cholecystokinin- analog ceruletide in healthy persons. Biol Psychiatry 37: 702-712. 1995 8.28
53 Schreiber H., Stolz-Born G., Kornhuber HH., Born J. Elektrophysio-logische Korrelate selektiver Aufmerksamkeit bei Kindern und Jugendlichen mit erhöhtem Schizophrenie-Risiko. Z Kinder-Jugendpsychiat 24: 282-292. 1996 0.99
54 Lieb K., Denz E., Hess R., Schüttler R., Kornhuber HH., Schreiber H. Preattentive information processing as measured by backward masking and texton detection tasks in adolescents at high genetic risk for schizophrenia. Schizophr Res 21: 171-182. 1996 4.74
55 Schreiber H., Stolz-Born G., Kornhuber HH., Born J. Event-related brain potentials and psychometric performance in adolescents at genetic risk for schizophrenia. Ogura C, Koga Y, Schimokochi M (eds). Recent advances in event-related potential research Elsevier, Amsterdam. pp. 550-557. 1996
56 Sperfeld A., Schreiber H., Reindl I., Kleber FX., Ludolph AC. Die Ergospirometrie - eine Methode zur Detektion mitochondrialer Cytopathien. Nervenarzt 70: 155-162. 1997 0.68
57 Schreiber H., Rothmeier J., Stolz-Born. G., Born J., Rothenberger A., Jürgens R., Becker W., Kornhuber HH. Visually-guided saccadic eye movements in adolescents at genetic risk for schizophrenia. Schizophr Res 25: 97-109. 1997 4.74
58 Rösche J., Maurer H., Schreiber H., Kornhuber HH. Normale somato-sensibel evozierte Potentiale beim Adie-Syndrom. Die Rolle der la-Fasern. Z EEG-EMG 28: 49-51. 1997 0.31
59 Heidegger S., Mattfeldt T., Rieber A., Wikstroem M., Kern P., Kern W., Schreiber H. Orbito-spenoidal Aspergillus infection mimicking cluster headache: a case report. Cephalalgia 17 :676-679. 1997 6.04
60 Schreiber H., Stolz-Born G., Kornhuber HH., Born J. Investigation of electrophysiological correlates of attention and information processing as vulnerability indicators for schizophrenia. J Psychophysiology, 12: 286-300. 1998 1.634
61 Schreiber H. Neurologische Manifestationen immunologischer Erkrankungen - Die Vaskulitiden. Ärztl. Praxis Neurol Psychiat 12: 628-638. 1998
62 Schreiber H., Baur-Seack K., Kornhuber HH., Wallner B., Friedrich JM., DeWinter IM., Born J. Brain morphology in adolescents at genetic risk for schizophrenia assessed by qualitative and quantitative magnetic resonance imaging. Schizophr Res 40: 81-86. 1999 4.74
63 Kern W., Born J., Schreiber H., Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48: 557-563. 1999 8.28
64 Schreiber H., Ludolph AC. Degenerative Erkrankungen des Nervensystems. Motoneuronerkrankungen und cerebelläre Ataxien.  Therapiehandbuch. Sonderdruck. München: Urbann & Schwarzenberg Verlag. P6, 1-19. 1999
65 Jürgens R., Becker., W., Schreiber H., Fegert B., Klausmann S. Saccadic tracking in schizophrenia: Incidence of hypometria and intrusions influenced by visual background and pace of stepping ? In Becker W, Deubel H & Mergner T (eds). CurrentOculomotor Research. Phsyiological and psychological aspects. New York: Plenum Press. Pp. 447-450.  1999
66 Busse K., Köhler J., Stegmann K., Progratz D., Koch MC., Schreiber H. An inherited 4q35 EcoRI-DNA-fragment of 35 kb in a family with a sporadic case of facio-scapulo-humeral muscular dystrophy (FSHD). Neuromusc Disord 10: 178-181. 2000 2.79
67 Wollinsky KH., Hülser PJ., Binkmeier H., Aulkemeyer P., Bössenecker W., Huber-Hartmann KH., Rohrbach P., Schreiber H., Weber F., Kron M., Büchele G., Mehrkens HH., Ludolph AC., Rüdel R. CSF filtration is an effective treatment of Guillain-Barre syndrome. A randomized clinical trial. Neurology 57: 774-7480. 2001 8.31
68 Koch MC., Schreiber H. Fazioskapulohumerale Muskeldystrophie - Klinische und molekulargenetische Aspekte. In R. Dengler & P. Pongratz (Hrsg). Management of Neuromuscular Diseases. Letter Nr. 21, pp. 1-12; München: Arcis-Verlag.  2001
69 Schreiber H. Störungen der peripheren Nerven. In F. Lehmann-Horn & A.C. Ludolph (Hrsg.): Neurologische Therapie. 3. Auflage. Urban & Fischer Verlag. Pp. 328-352. 2001
70 Schreiber H. Störungen des Bewegungsapparates. In F. Lehmann-Horn & A.C. Ludolph (Hrsg.): Neurologische Therapie. 3. Auflage. München: Urban & Schwarzenberg Verlag. Pp. 433-443. 2001
71 Butz M., Koch MC., Müller-Felber W., Lemmers RJLF., van der Maarek SM., Schreiber H. Facioscapulohumeral muscular dystrophy - phenotype-genotype corellation in patients with borderline D4Z4 repeat numbers. J Neurol 250: 932-937. 2003 3.47
72 Butz M., Wollinsky KH., Wiedemuth-Catrinescu U., Sperfeld A., Winter S., Mehrkens HH., Ludolph AC., Schreiber H. Longitudinal effects of noninvasive positive pressure ventilation in patients with amyotrophic lateral sclerosis. Am J Phys Med Rehabil 82(8): 597-604. 2003 1.58
73 Walter MC., Braun C., Vorgerd C., Poppe M., Thirion C., Schmidt C., Schreiber H., Knirsch U., Brummer D., Müller-Felber W., Pongratz D., Müller-Höcker J., Hübner A., Lochmüller H. Variable reduction of caveolin-3 in patients with LGMD2B/MM. J Neurol 250:1431-1438. 2003 3.47
74 Sperfeld AD., Karitzky J., Brummer D., Schreiber H., Häussler J., Ludolph AC., Hanemann CO. X-linked bulbospinal neuronopathy. Kennedy Disease. Arch Neurol (JAMA Neurology) 59: 1921-1926. 2003 3.47
75 Schreiber H. Les dysferlinopathies. Observations longitudinales de données cliniques, paracliniques et de l´imagerie á résonance magnétique dans des familles regroupant des membres symptomatiques et présymptomatiques. Diplóme de Myologie. Univ. Pierre et Marie Curie. Sorbonne VI. CHU Pitié-Salpêtriére. Paris. 2003
76 Walter MC., Petersen JA., Stucka R., Fischer D., Schröder R., Vorgerd M., Schroers A., Schreiber H., Hermann CO., Knirsch U., Rosenbohm A., Huebner A., Barisic N., Horvath R., Komoly S., Reilich P., Müller-Felber W., Pongratz D., Müler JS., Auerswald EA., Lochmüller H. FKRP (826>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet 41 (4): 1-7. 2004 6.36
77 Brummer D., Walter MC., Palmbach M., Knirsch U., Karitzky J., Tomczak R., Braun C., Grundhoff N., Bornemann A., Müller CR., Lochmüller H., Schreiber H. Long-term MRI and clinical follow-up of symptomatic and presymptomatic carriers of dysferlin gene mutations. Acta Myologica 24(1): 6-16. 2005 0.51
78 Schreiber H., Gaigalat T., Wiedemuth-Catrinescu U., Graf M., Uttner I., Muche R., Ludoph AC. Cognitive function in bulbar- and spinal-onset ALS - a longitudinal study in 52 patients. J Neurol 252: 772-2781. 2005 3.47
79 Jurkat-Rott K., Schreiber H., Goebel HH., Lehmann-Horn F. Progressive Muskeldystrophien, Myotonien, periodische Paralysen, distale und kongenitale Myopathien. In Wallesch CW (Hrsg.) Neurologie. Diagnostik und Therapie in Klinik und Praxis. 1. Auflage. Kapitel 57, 797-817. Elsevier. Urban & Fischer. 2005
80 Uttner I., Mottaghy FM., Schreiber H., Riecker A., Ludolph AC., Kassubek J. Primary progressive aphasia accompanied by environmental sound agnosia: a neurophsychological, MRI and PET study.  Psychiatry Research: Neuroimaging 146: 191.197. 2006 2.96
81 Deschauer M., Morgenroth A., Joshi PR., Gläser D., Chinnery PP., Aasly J., Schreiber H., Knape M., Zierz S., Vorgerd M. Analysis of spectrum and frequencies of mutations in Mc Ardle diesease. J Neurol 254(6): 797-802. DOI: 10.1007/S004-006-0447-x (online) . 2007 3.47
82 Bengel D., Susa M., Schreiber H., Ludolph AC., Tumani H. Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rRNA gene sequence.  Eur J Neurol 14(9): 1067-1070. 2007 3.85
83 Pinkhardt EH., Jürgens R., Graf M., Ecker D., Born J., Becker W., Ludoplph AC., Schreiber H. Signs of impaired selective attention in patients with amyotrophic lateral sclerosis (ALS). J Neurol 255: 532-538. 2008 3.47
84 Riesner H., Zeitler C., Schreiber H., Wild A. Eine additive Therapie chronischer Schmerzen bei fortgeschrittener Gon/Coxathrose mit dem selektiven Serotonin-Reuptake-Hemmer Fluvoxamin (Fevarin). Z Orthop Unfall 146: 742-746. 2008 0.42
85 Sperfeld AD., Müller HP., Unrath A., Jüngling F., Uttner I., Schreiber H., Ludolph AC., Kassubek J. Die zentralnervöse Begleitung der spino-bulbären Muskelatrophie Typ Kennedy: ganzhirnbasierte, multiparametische MRT-Untersuchungen und neuropsychologische Befunde. Akt Neurologie DOI: 10.1055/s-0029-1338905. 2009 0.32
86 Soukup GR., Sperfeld AD., Uttner., I., Karitzky J., Ludolph AC., Kassubek J., Schreiber H. Fronto-temporale cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled study in 20 patients. J Neurol, 256: 1869-1875. 2009 3.47
87 Cepok S., Schreiber H., Hoffmann S., Zhou D., Neuhas O., von Geldern G., Hochgesand S., Nessler S., Rothenhammer V., Lang M., Hartung HP., Hemmer B. Enhancement of chemokine expression by interferon beta therapy in patiens with multiple sclerosis. Arch Neurol 66: 1-8. 2009 7.58
88 Devonshire V., Arbizu T., Borre B., Lang M., Lugaresi A., Singer B., Verdun di Cantogno E., Cornelisse P. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol. 2010; 10:28. doi: 10.1186/1471-2377-10-28. 2010
89 Schreiber H., Kiltz K., Lang M., Flachenecker P., Meissner H., Freidel M., Herbst H., Scholz E., Hofmann W., Schlegel E., Elias W., Gehring K., Eckhardt U., Bergmann A., Reifschneider G., Ries S., Rupp E., Ring C. Fatigue, Kognition und Persönlichkeit bei Patienten mit schubförmiger MS (RRMS). Der Nervenarzt 81: 39-40. 2010 0.86
90 Bischoff C., Schreiber H., Bergmann A. Background information on multiple sclerosis patients stopping ongoing immunmodulatory therapy: a multi-center study in a community-based inviorment. J Neurol 259: 2347-2353. 2012 3.47
91 Sarkozy A., Deschauer M., Carlier RY., Schrank B., Seeger J., Wakter MC., Schoser B., Reilich P., Leturq F., Radunovic A., Laforet P., Eymard B., Schreiber H., Hicks D., Vaidya SS., Gläser D., Carlier PG., Bushby K., Lochmüller H., Straub V. Muscle MRI findings in limb girdle muscular dystrophy typ 2L. Neuromusc Disorders 22: Suppl. 2: S122-129. 2012 2.79
92 Korinna Karampampa1,2, Anders Gustavsson1*,3, Carolin Miltenburger4*, Katja Neidhardt5 and Michael Lang6 Treatment experience, burden and
unmet needs (TRIBUNE) in MS study: results from Germany
Multiple Sclerosis Journal
18(6) (Suppl 2): 23–27
2012
93 Braune S., Lang M., Bergmann A., NTD Study Group. Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort. J Neurol. 2013 (12): 2981-5. doi: 10.1007/s00415-013-7082-0. Epub 2013. 2013
94 Boeru G., Milanov I., De Robertis F., Kozubski W., Lang M., Rojas-Ferrares S., Tomlinson M. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices (Auckl). 2013 Nov 15; 6: 175-84. doi: 10.2147/MDER.S52590. eCollection 2013. 2013
95 Sarkozy A., Hicks D., Hudson J., Laval SH., Barresi R., Hilton-Jones D., Dreschauer M., Harris E., Rufibach L., Hwang E., Bashir R., Walter MC., Krause S., van den Bergh P., Illa I., Pénisson-Besnier H., De Waele L., Runbull D., Guglieri M., Schrank B., Schoser B., Seeger J., Schreiber H., Gläster D., Ray P., Schapira AH, Swingler R., Turner C., Wagner KR., Maddison P., Shaw PJ., Straub V., Bushby K., Lochmüller M. ANO5 gene analysis in a large cohort of patients with anoctaminopathy: confirmation of male prevalence and high occurrence of the common exon 5 gene mutation. Human Mutat 34: 1111-1118. 2013 5.05
96 Walter MC., Reilich P., Thiele S., Schessl J., Schreiber H., Reiners K., Kress W., Müller-Reible C., Vorgerd M., Urban P., Schrank B., Deschauer M., Schlotter-Weigel B., Kohnen R., Lochmüller H. Treatment of diysferlinopathy with deflacort. A double-blind, placebo-controlled clinical trial. Orphanet J of Rare Dis 8(1): 26ff. 2013 5.07
97 Freidel M., Tiel-Wilck K., Schreiber H., Prechtl A., Essner U., Lang M. Drugresistant MS spasticity treatment with Sativex add-on and driving ability. Acta Neurol Scand: DOI: 10.1111/ane. 12287. 2014 2.44
98 Baum K., Boldt HJ., Chan A., Harms L., Hartung HP., Kieseier BC., Korn T., Mäurer M., Meier U., Schreiber H., Tackenburg B., Wiendl H., Hziemssen T., Gold R. Dimethylfumarat in der Therapie der schubförmigen MS. Verträglichkeit und Management von Nebenwirkungen. Nervenheilkunde 33: 175-179. 2014
99 Freidel M., Tiel-Wilck K., Schreiber H., Prechtl A., Essner U., Lang M. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability. Acta Neurol Scand. 2015 Jan; 131(1) :9-16. doi: 10.1111/ane.12287. Epub 2014 Sep 11. 2015
100 Schreiber H., Lang M., Kiltz K., Lang C. Is personality profile a relevant determinant of fatigue in multiple sclerosis? Front Neurol. 2015 Feb 4;6:2. doi: 10.3389/fneur.2015.00002. eCollection 2015. 2015
101 Rau D., Lang M., Harth A., Naumann M., Weber F., Tumani H., Bayas A. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases. Int J Mol Sci. 2015 Jun 29;16(7):14669-76. doi: 10.3390/ijms160714669. 2015
102 Kolber P., Luessi F., Meuth SG., Klotz L., Korn T., Trebst C., Tackenberg B., Kieseier B. Kümpfel T., Fleischer V., Tumani H., Wildemann B., Lang M., Flachenecker P., Meier U., Brück W., Limmroth V., Haghikia A., Hartung HP., Stangel M., Hohlfeld R., Hemmer B., Gold R., Wiendl H., Zipp F. Current aspects of therapy conversion for multiple sclerosis. Nervenarzt. 2015 Oct; 86(10): 1236-47. doi: 10.1007/s00115-015-4368-8. 2015
103 Ziemssen T., Rauer S., Stadelmann C., Henze T., Koehler J., Penner IK., Lang M., Poehlau D., Baier-Ebert M., Schieb H., Meuth S. Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. PLoS One. 2015 Sep 22; 10(9): e0138243. doi: 10.1371/journal.pone.0138243. eCollection 2015. 2015
104 Ziemssen T., Albrecht H., Haas J., Klotz L., Lang M., Lassek C., Schmidt S., Tackenberg B., Cornelissen C. 36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice. Value Health. 2015 Nov;18(7): A749. doi: 10.1016/j.jval.2015.09.2894. Epub 2015 Oct 20. 2015
105 Trenkwalder C., Canelo M., Lang M., Schroeder H., Kelling D., Berkels R., Schollmayer E., Heidbrede T., Benes H. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2015 Nov 11. pii: S1389-9457(15)02018-3. doi: 10.1016/j.sleep.2015.10.006. [Epub ahead of print]. 2015
106 Schreiber H., Lang M., Kiltz K., Lang C. Is personality profile a relevant determinant of fatigue in multiple sclerosis. Front. Neurol- Vol. 6; 2; 1-7. doi: 10.3389/fneur.2015.00002. 2015
107 Braune S., Lang M., Bergmann A., NeuroTransData Study Group. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J Neurol. 2016 Feb;263(2): 327-33. doi: 10.1007/s00415-015-7970-6. Epub 2015 Dec 8. 2016
108 Klotz L., Berthele A., Brück W., Chan A., Flachenecker P., Gold R., Haghikia A., Hellwig K., Hemmer B., Hohlfeld R., Korn T., Kümpfel T., Lang M., Limmroth V., Linker RA., Meier U., Meuth SG., Paul F., Salmen A., Stangel M., Tackenberg B., Tumani H., Warnke C., Weber MS., Ziemssen T., Zipp F., Wiendl H. Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action Nervenarzt. 2016 Jun; 87(6): 645-59. doi: 10.1007/s00115-016-0077-1. 2016
109 Adam Strzelczyk, Arnfin Bergmann, Valeria Biermann, Stefan Braune, Lienhard Dieterle, Bernhard Forth, Lena-Marie Kortland, Michael Lang, Thomas Peckmann, Oliver Schöffski, Karl-Otto Sigel, Felix Rosenowa Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany Epilepsy & Behavior 64 (2016) 75–82 2016
110 U. K. Zettl, H. Schreiber, U. Bauer-Steinhusen, T. Glaser, K. Hechenbichler, M. Hecker; for the BETAPATH Study Group   Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis Acta Neurol Scand 2016; 1–6 2016
111 Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H. Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German. 2016
112 Ingo Kleiter1, Michael Lang2, Judith Jeske3, Christiane Norenberg4, Barbara Stollfuß5, Markus Schürks6 BETAEVAL- Adherence and satisfaction with the BETACONNECT BMC Neurol. 2017; 17: 174.(Published online 2017 Sep 6. doi:  10.1186/s12883-017-0953-8) 2017
113 Gereon Nelles, Michael Lang Teleneurologie – Chancen und Risiken Forum neurologicum der Deutschen Gesellschaft für Neurologie; Thieme 2017 ; Akt Neurol 2017; 44: 126–143 2017
114 David OJ1, Berwick A2, Pezous N1, Lang M3, Tiel-Wilck K4, Ziemssen T5, Li P6, Hara H1, Schmouder R7. Determination of seminal concentration of fingolimod and fingolimod-phosphate in multiple sclerosis patients receiving chronic treatment with fingolimod Clin Pharmacol Drug Dev. 2017 Dec 19. doi: 10.1002/cpdd.424. [Epub ahead of print] 2017
115 Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod after 1 Year of Treatment: Initial Results from the Observational, Non-Interventional Study PANGAEA Neurotherapeutics. 2017 Dec 22. doi: 10.1007/s13311-017-0595-y. [Epub ahead of print] 2017
116 Limmroth V1, Ziemssen T2, Lang M3, Richter S4, Wagner B4, Haas J5, Schmidt S6, Gerbershagen K1, Lassek C7, Klotz L8, Hoffmann O9, Albert C9, Schuh K10, Baier-Ebert M10, Wendt G10, Schieb H10, Hoyer S10, Dechend R11, Haverkamp W12. Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7. 2017
117 Trenkwalder C1, Canelo M2, Lang M3, Schroeder H4, Kelling D4, Berkels R4, Schollmayer E4, Heidbrede T4, Benes H5. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2017 Feb;30:257-265. doi: 10.1016/j.sleep.2015.10.006. Epub 2015 Nov 11. 2017
118 A. Schmitt, B. Rall, I. Haase, J. Durner, H. Schreiber (2017).   Vergleich eines Roboter-gestützten Gangtrainings mit konventionellem Gangtraining bei Patienten mit fortgeschrittenem idiopathischen Parkinson-Syndrom.  Neurol Rehabil 2017; 23(3): 237-246. 2017
119 M. Filser, H. Schreiber, M. Lang, J. Pöttgen, S. Ullrich, I.K. Penner The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): Results from the German validation study Journal of Neurology / https://doi.org/10.1007/s00415-018-9034-1 J Neurol. 2018 Nov;265(11):2587-2593. 2017
120 Kleiter I, Lang M, Jeske J, Norenberg C, Stollfuss B, Schurks M.  Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT(R) autoinjector: a prospective observational cohort study. BMC Neurol. 2017;17(1):174 2017
121 Ziemssen et al. Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany accepted Neuroimmunology & Neuroinflammation MS ID#: NEURIMMINFL/2018/017921 2019
122 Tjalf Ziemssen, Michael Lang, Björn Tackenberg, Stephan Schmidt, Holger Albrecht, Luisa Klotz, Judith Haas, Christoph Lassek, Christian Cornelissen, Benjamin Ettle, on behalf of the PANGAEA study group Long-term  real-world evidence  for sustained clinical benefits of fingolimod following switch from natalizumab submitted 2019
123 Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol. 2018 Nov 16. doi: 10.1007/s00415-018-9117-z. 2018
124 Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group. Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA. Neurotherapeutics. 2018 Jan;15(1):190-199. doi: 10.1007/s13311-017-0595-y. 2018
125 David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R. Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod. Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221. doi: 10.1002/cpdd.424. Epub 2017 Dec 19. 2018




Umsetzung: artifox.com



Neurologie Ulm | Tinnitus Therapie Centrum Ulm | BEGUMED GmbH | Physioconcept Ulm | Psychotherapie Arian (HPG) | NeuroTransConcept | NeuroTransData
ulmmed | PatientConcept App | NeuroSys GmbH |